< Terug naar vorige pagina
Publicatie
Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
Tijdschriftbijdrage - Tijdschriftartikel
An open-label, multi-center, expanded access study was conducted in patients with advanced neuroendocrine tumors (NET) treated with everolimus (10 mg/day) to assess safety and health-related quality of life (HRQOL).
Tijdschrift: Targeted Oncology
ISSN: 1776-2596
Issue: 5
Volume: 11
Pagina's: 667 - 675
Jaar van publicatie:2016
BOF-keylabel:ja
IOF-keylabel:ja
BOF-publication weight:1
CSS-citation score:1
Auteurs:International
Authors from:Higher Education
Toegankelijkheid:Closed